{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:02:56Z","timestamp":1771927376086,"version":"3.50.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"\n Background<\/jats:title>\n Stupor is a severe psychomotor syndrome with motor retardation and speech inhibition, that adversely affects outcomes. Benzodiazepines and electroconvulsive therapy (ECT) are standard treatments, yet individual responses vary considerably, highlighting the need for effective clinical predictors.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aimed to identify clinical predictors of therapeutic response in patients with stupor to facilitate individualized treatment.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We conducted a retrospective observational study including 45 patients with stupor hospitalized at Shandong Daizhuang Hospital between January 2010 and August 2024. Finally, 40 patients met the inclusion criteria and were retained for analysis. Patients were classified as responders or non-responders based on Clinical Global Impression-Improvement (CGI-I) scores at two weeks. Demographic characteristics, clinical variables, and medication regimens, including antipsychotics, benzodiazepines, and ECT use, were extracted from medical records. Peripheral blood inflammatory markers were also collected and analyzed. Mann-Whitney\n U<\/jats:italic>\n tests, chi-square tests, logistic regression analyses, and receiver operating characteristic (ROC) curves were used to identify predictive factors and evaluate their diagnostic accuracy.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among 40 patients, 24 (60.00%) responded favorably. Responders were more likely to receive ECT (\n \n \u03c7\n 2<\/jats:sup>\n <\/jats:italic>\n = 6.667,\n P<\/jats:italic>\n = 0.010), higher chlorpromazine equivalent doses (\n |Z|<\/jats:italic>\n = 3.418,\n P<\/jats:italic>\n = 0.001), and olanzapine (\n \n \u03c7\n 2<\/jats:sup>\n <\/jats:italic>\n = 4.365,\n P<\/jats:italic>\n = 0.037), while inflammatory markers showed no differences. Logistic regression identified chlorpromazine equivalent dose as an independent predictor (\n OR<\/jats:italic>\n = 1.007, 95%\n CI<\/jats:italic>\n : 0.998-1.017,\n P<\/jats:italic>\n = 0.045). ROC analysis suggested a data-driven, exploratory optimal predictive chlorpromazine-equivalent dose of approximately 108 mg (about 100\u2013110 mg) (AUC = 0.820, 95%\n CI<\/jats:italic>\n : 0.677-0.963), corresponding to roughly 4.3-5.4 mg of olanzapine.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n A higher chlorpromazine-equivalent dose and olanzapine use were associated with short-term therapeutic response in stupor, independent of ECT. ROC analysis suggested a data-driven, exploratory cut-off of approximately 108 mg (about 100\u2013110 mg) chlorpromazine-equivalent, which should not be interpreted as a prescriptive clinical threshold. However, these findings are preliminary, limited to two-week outcomes in a modest retrospective sample. The role of inflammation in stupor remains inconclusive, and further studies are warranted to clarify its predictive value.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1714338","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:03:27Z","timestamp":1769169807000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical predictors of short-term treatment response in stupor: a retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xin","family":"Zong","sequence":"first","affiliation":[{"name":"Shandong Daizhuang Hospital","place":["Jining, Shandong, China"]},{"name":"School of Mental Health, Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqian","family":"Liu","sequence":"additional","affiliation":[{"name":"Shandong Daizhuang Hospital","place":["Jining, Shandong, China"]},{"name":"School of Mental Health, Jining Medical University","place":["Jining, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Shandong Daizhuang Hospital","place":["Jining, Shandong, China"]},{"name":"Jining Key Laboratory of Neuromodulation","place":["Jining, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenchen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shandong Daizhuang Hospital","place":["Jining, Shandong, China"]},{"name":"Jining Key Laboratory of Neuromodulation","place":["Jining, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong Daizhuang Hospital","place":["Jining, Shandong, China"]},{"name":"Jining Key Laboratory of Neuromodulation","place":["Jining, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong Daizhuang Hospital","place":["Jining, Shandong, China"]},{"name":"Jining Key Laboratory of Neuromodulation","place":["Jining, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baohua","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong Daizhuang Hospital","place":["Jining, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2116304","article-title":"Catatonia","volume":"389","author":"Heckers","year":"2023","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2023-0113","article-title":"The diagnosis and treatment of catatonia","volume":"23","author":"Rogers","year":"2023","journal-title":"Clin Med (Lond)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30190-7","article-title":"Catatonia and the immune system: a review","volume":"6","author":"Rogers","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.7.1233","article-title":"Catatonia in psychiatric classification: a home of its own","volume":"160","author":"Taylor","year":"2003","journal-title":"Am J Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/PSY.0000000000000574","article-title":"Catatonic stupor in schizophrenic disorders and subsequent medical complications and mortality","volume":"80","author":"Funayama","year":"2018","journal-title":"Psychosom Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcu118","article-title":"An undiagnosed stupor in the acute medical unit: a case of Malignant catatonia","volume":"108","author":"Adams","year":"2015","journal-title":"Qjm"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231158232","article-title":"Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology","volume":"37","author":"Rogers","year":"2023","journal-title":"J Psychopharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1080\/10401230701844786","article-title":"Catatonic syndrome: importance of detection and treatment with lorazepam","volume":"20","author":"Seethalakshmi","year":"2008","journal-title":"Ann Clin Psychiatry"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-09499-2","article-title":"Joint clinical practice guideline on benzodiazepine tapering: considerations when risks outweigh benefits","volume":"40","author":"Brunner","year":"2025","journal-title":"J Gen Intern Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.2007.19.4.406","article-title":"Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes","volume":"19","author":"Carroll","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000400268.60537.5e","article-title":"Memantine and catatonia: a case report and literature review","volume":"17","author":"Obregon","year":"2011","journal-title":"J Psychiatr Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/bdi.12348","article-title":"Catatonia in 26 patients with bipolar disorder: clinical features and response to electroconvulsive therapy","volume":"17","author":"Medda","year":"2015","journal-title":"Bipolar Disord"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-017-0819-5","article-title":"Is electroconvulsive therapy an evidence-based treatment for catatonia? A systematic review and meta-analysis","volume":"79","author":"Leroy","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S231573","article-title":"Electroconvulsive therapy for patients with catatonia: current perspectives","volume":"16","author":"Lloyd","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2023.04.004","article-title":"Catatonia and ECT across the lifespan","volume":"263","author":"Karl","year":"2024","journal-title":"Schizophr Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.schres.2022.09.021","article-title":"Clozapine as a treatment for catatonia: A systematic review","volume":"247","author":"Saini","year":"2022","journal-title":"Schizophr Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1192\/j.eurpsy.2025.9","article-title":"The use of antipsychotics in the treatment of catatonia: a systematic review","volume":"70","author":"Redon","year":"2025","journal-title":"Eur Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.08.040","article-title":"Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs","volume":"67","author":"Gardner","year":"2010","journal-title":"Biol Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12991-023-00471-0","article-title":"Catatonia-like behavior and immune activation: a crosstalk between psychopathology and pathology in schizophrenia","volume":"22","author":"Messina","year":"2023","journal-title":"Ann Gen Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1590\/0101-60830000000232","article-title":"Neutrophil-lymphocyte ratio in catatonia","volume":"47","author":"Sahin","year":"2020","journal-title":"Arch Clin Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3390\/jcm10091924","article-title":"Neutrophil-to-lymphocyte ratio, a novel inflammatory marker, as a predictor of bipolar type in depressed patients: a quest for biological markers","volume":"10","author":"Dionisie","year":"2021","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2243820","article-title":"Clozapine for treatment refractory catatonia in individuals with autism spectrum disorder: a retrospective chart review study","volume":"16","author":"Thom","year":"2023","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1192\/j.eurpsy.2024.1768","article-title":"The minimal important difference in obsessive-compulsive disorder: an analysis of double-blind SSRI trials in adults","volume":"67","author":"Cohen","year":"2024","journal-title":"Eur Psychiatry"},{"key":"B25","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.12788\/cp.0103","article-title":"Switching antipsychotics: A guide to dose equivalents","volume":"20","author":"Thippaiah","year":"2021","journal-title":"Curr Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2015.03.021","article-title":"Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials","volume":"180","author":"Hayasaka","year":"2015","journal-title":"J Affect Disord"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.schres.2018.12.017","article-title":"Neutrophil-to-lymphocyte ratio in schizophrenia: A systematic review and meta-analysis","volume":"206","author":"Karageorgiou","year":"2019","journal-title":"Schizophr Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1186\/s12888-024-06330-w","article-title":"Neutrophil\/lymphocyte ratio is increased in the acute phase of schizophrenia and regardless the use and types of antipsychotic drugs","volume":"24","author":"Zheng","year":"2024","journal-title":"BMC Psychiatry"},{"key":"B30","volume-title":"Practice guideline for the treatment of patients with schizophrenia","year":"2020"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/026988110101500412","article-title":"Lethal catatonia responding to high-dose olanzapine therapy","volume":"15","author":"Cassidy","year":"2001","journal-title":"J Psychopharmacol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2021.29202.bjc","article-title":"Catatonic symptoms successfully treated with olanzapine in an adolescent with schizophrenia","volume":"31","author":"Kufert","year":"2021","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e5864","DOI":"10.1002\/bmc.5864","article-title":"Olanzapine-induced weight gain and lipid dysfunction in mice between different gender","volume":"38","author":"Zhu","year":"2024","journal-title":"BioMed Chromatogr"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20240738","article-title":"Antipsychotic drugs: A concise review of history, classification, indications, mechanism, efficacy, side effects, dosing, and clinical application","volume":"181","author":"Leucht","year":"2024","journal-title":"Am J Psychiatry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e2693","DOI":"10.1002\/hup.2693","article-title":"Effects of olanzapine during cognitive and emotional processing in schizophrenia: A review of functional magnetic resonance imaging findings","volume":"34","author":"Del Fabro","year":"2019","journal-title":"Hum Psychopharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291720001853","article-title":"Brain imaging in catatonia: systematic review and directions for future research","volume":"50","author":"Haroche","year":"2020","journal-title":"Psychol Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1040443","article-title":"Electroconvulsive therapy for obsessive-compulsive disorder: A retrospective study","volume":"13","author":"Li","year":"2022","journal-title":"Front Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.09050703","article-title":"ECT in the treatment of a patient with catatonia: consent and complications","volume":"167","author":"Zisselman","year":"2010","journal-title":"Am J Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04746blu","article-title":"Electroconvulsive therapy decreases dopamine D2 receptor binding in the anterior cingulate in patients with depression","volume":"71","author":"Saijo","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.5152\/alphapsychiatry.2024.231473","article-title":"Efficacy of modified electroconvulsive therapy in treatment-resistant schizophrenia","volume":"25","author":"Chen","year":"2024","journal-title":"Alpha Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-011-0285-4","article-title":"Response rate of catatonia to electroconvulsive therapy and its clinical correlates","volume":"262","author":"Raveendranathan","year":"2012","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.36131\/cnfioritieditore20250306","article-title":"Does dysregulation of the indirect pathway contribute to the pathophysiology of catatonia through neurotransmitter imbalance","volume":"22","author":"Seif","year":"2025","journal-title":"Clin Neuropsychiatry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaclp.2025.05.001","article-title":"Catatonia: american psychiatric association resource document","volume":"66","author":"Wilson","year":"2025","journal-title":"J Acad Consult Liaison Psychiatry"},{"key":"B45","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1055\/a-2195-1499]","article-title":"The effect of electroconvulsive therapy on specific catatonia symptoms and predictors of late response","volume":"57","author":"Breit","year":"2024","journal-title":"Pharmacopsychiatry"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbaa041","article-title":"Higher serum C-reactive protein levels in catatonic patients: A comparison to non-catatonic patients and healthy controls","volume":"46","author":"Zhou","year":"2020","journal-title":"Schizophr Bull"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2018.03.012","article-title":"Neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio in mood disorders: A meta-analysis","volume":"84","author":"Mazza","year":"2018","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2022.07.006","article-title":"Neutrophil-lymphocyte ratios as inflammatory biomarkers in psychiatric patients","volume":"105","author":"Bhikram","year":"2022","journal-title":"Brain Behav Immun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1334415","article-title":"Correlation between inflammatory markers over time and disease severity in status epilepticus: a preliminary study","volume":"15","author":"Shi","year":"2024","journal-title":"Front Neurol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"107134","DOI":"10.1016\/j.psyneuen.2024.107134","article-title":"Complete blood count-based inflammation indexes and symptom severity in people with schizophrenia spectrum disorders: An analysis based on structural equation modelling","volume":"168","author":"Cavaleri","year":"2024","journal-title":"Psychoneuroendocrinology"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1714338\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T09:10:41Z","timestamp":1771924241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1714338\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":50,"alternative-id":["10.3389\/fpsyt.2025.1714338"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1714338","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"article-number":"1714338"}}